Comparative Pharmacology
Head-to-head clinical analysis: PROFERDEX versus VENOFER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROFERDEX versus VENOFER.
PROFERDEX vs VENOFER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PROFERDEX (iron dextran) is a colloidal solution of ferric hydroxide in complex with dextran, providing a source of iron for hemoglobin synthesis and erythropoiesis. Iron is incorporated into heme, which is essential for oxygen transport in red blood cells.
Iron replacement therapy; iron is essential for hemoglobin synthesis and oxygen transport. VENOFER (iron sucrose) provides elemental iron that binds to transferrin for transport to erythroid precursor cells.
100 mg intramuscular or intravenous every 3 to 7 days; may increase to 200 mg per dose.
Adult: 5 mL (100 mg elemental iron) IV push at 1 mL/min or IV infusion over 15-30 minutes, given 1-3 times per week to a total cumulative dose based on iron deficit calculation using Ganzoni formula.
None Documented
None Documented
Terminal half-life approximately 20-30 hours in patients with normal hepatic function; prolonged in hepatic impairment. Clinical context: supports every-3-week dosing.
5-6 hours (initial phase, redistribution); terminal half-life ~14 hours (iron clearance from plasma). Clinical context: reflects iron utilization and storage, not elimination of drug.
Primarily fecal (biliary excretion of iron from degraded RBCs, about 80-90%); renal excretion negligible (<5% unchanged).
Primarily reticuloendothelial system; iron is incorporated into hemoglobin and stored as ferritin/hemosiderin. Minimal renal excretion (<1% unchanged). Fecal elimination negligible. Small amounts lost via desquamation, blood loss, and menstruation.
Category C
Category C
Iron Replacement
Iron Replacement